BioJapan 2025

Richmond Pharmacology is excited to confirm our attendance at BioJapan 2025, Asia’s leading biotechnology partnering event, taking place in Yokohama from 8th –10th October. Representing Richmond at BioJapan: Dr Jörg Täubel, Chief Executive Officer Dr Ulrike Lorch, Chief Medical Director Stephen Wilkinson, Business Development Manager Nobuo Ittetsu, Head of Japanese Volunteer Recruitment Minoru Takada, Japanese Business Development Executive We look forward to connecting with global partners, sharing insights and exploring opportunities in: • Early-phase trials for biologics and advanced therapies • UK–Japan collaboration in gene editing and RNA medicines • Regulatory strategy across Asia and Europe • Bridging studies and multi-regional trial design • Patient-centric and adaptive trial models If you’re attending BioJapan 2025 and are looking to collaborate in translational research or clinical development, get in touch to arrange a meeting: info@richmondpharmacology.com